Wordt geladen...
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
One of the most significant therapeutic challenges in the treatment of ovarian cancer is the development of recurrent platinum-resistant disease. Cancer stem cells (CSCs) are postulated to contribute to recurrent and platinum-resistant ovarian cancer (OvCa). Drugs that selectively target CSCs may au...
Bewaard in:
| Gepubliceerd in: | Cancers (Basel) |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6896080/ https://ncbi.nlm.nih.gov/pubmed/31671803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11111678 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|